REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has announced a conference call scheduled for Thursday, August 1, 2024, at 4:30 p.m. ET. The purpose of this call is to discuss the company's financial results for the second quarter ended June 30, 2024, along with recent operational highlights. Interested parties can access the live call by phone or via webcast on the REGENXBIO website. For phone access, dial (646) 307-1963 (domestic) or (800) 715-9871 (international) with passcode 4849384. The recorded webcast will be available for approximately 30 days after the call. Participants are advised to join 15 minutes before the start time.

ROCKVILLE, Md., July 25, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent operational highlights.

To access the live call by phone, dial (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 4849384. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-1-to-discuss-second-quarter-2024-financial-results-and-recent-operational-highlights-302206370.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO (RGNX) hosting its Q2 2024 earnings call?

REGENXBIO (RGNX) is hosting its Q2 2024 earnings call on Thursday, August 1, 2024, at 4:30 p.m. ET.

How can investors access REGENXBIO's (RGNX) Q2 2024 earnings call?

Investors can access REGENXBIO's Q2 2024 earnings call by phone at (646) 307-1963 (domestic) or (800) 715-9871 (international) with passcode 4849384, or via webcast on the company's website at www.regenxbio.com.

What period will REGENXBIO's (RGNX) Q2 2024 financial results cover?

REGENXBIO's Q2 2024 financial results will cover the quarter ended June 30, 2024.

How long will the recorded webcast of REGENXBIO's (RGNX) Q2 2024 earnings call be available?

The recorded webcast of REGENXBIO's Q2 2024 earnings call will be available for approximately 30 days following the call.